The Duration Study

Inclusion Criteria: * Histologically confirmed diagnosis of non-myeloid malignancy * Baseline hemoglobin value \>= 11 g/dL and \<= 12 g/dL unrelated to transfusion * Female patients with reproductive potential must have a negative serum pregnancy test at screening. Patients must have signed an informed consent Exclusion Criteria: * Uncontrolled hypertension * History (within 6 months) of uncontrolled cardiac arrhythmias, or history of pulmonary emboli, deep vein thrombosis, ischemic stroke, other arterial or venous thrombotic events (excluding superficial thromboses), or known history of chronic coagulation disorder * Transfusion within 28 days prior to first dose * Planned myelosuppressive chemotherapy or radiation during study and no prior chemotherapy within 8 weeks or radiation within 4 weeks of study entry.